These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463 [TBL] [Abstract][Full Text] [Related]
23. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873 [TBL] [Abstract][Full Text] [Related]
24. Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa). Pollastro F; Taglialatela-Scafati O; Allarà M; Muñoz E; Di Marzo V; De Petrocellis L; Appendino G J Nat Prod; 2011 Sep; 74(9):2019-22. PubMed ID: 21902175 [TBL] [Abstract][Full Text] [Related]
25. Rimonabant: more than an anti-obesity drug? Costa B Br J Pharmacol; 2007 Mar; 150(5):535-7. PubMed ID: 17245359 [TBL] [Abstract][Full Text] [Related]
26. Recent advances in CB1 cannabinoid receptor antagonists. Lange JH; Kruse CG Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959 [TBL] [Abstract][Full Text] [Related]
27. [Cannabis and cannabinoids as drugs]. Khiabani HZ; Mørland J Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810 [TBL] [Abstract][Full Text] [Related]
32. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. Scheen AJ J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513 [TBL] [Abstract][Full Text] [Related]
33. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Gadde KM; Allison DB Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206 [No Abstract] [Full Text] [Related]
34. Obesity drug development - CBI's 2nd Annual Summit. Heal DJ IDrugs; 2006 Oct; 9(10):682-5. PubMed ID: 17016771 [No Abstract] [Full Text] [Related]
35. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. Antel J; Gregory PC; Nordheim U J Med Chem; 2006 Jul; 49(14):4008-16. PubMed ID: 16821760 [No Abstract] [Full Text] [Related]
36. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138 [TBL] [Abstract][Full Text] [Related]
37. [The endocannabinoid system and treatment of obesity]. Aronsen L Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201 [TBL] [Abstract][Full Text] [Related]
38. Role of cannabinoids in the development of fatty liver (steatosis). Purohit V; Rapaka R; Shurtleff D AAPS J; 2010 Jun; 12(2):233-7. PubMed ID: 20204561 [TBL] [Abstract][Full Text] [Related]
39. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Croci T; Zarini E Br J Pharmacol; 2007 Mar; 150(5):559-66. PubMed ID: 17245360 [TBL] [Abstract][Full Text] [Related]
40. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]